^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA synthesis inhibitor

    Related drugs:
    19h
    DUET-UC-NK: Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Beijing Biotech
    New P1 trial • First-in-human
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    cyclophosphamide • fludarabine IV
    22h
    PROHEAR: ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin (clinicaltrials.gov)
    P2, N=40, Completed, Acousia Therapeutics GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin
    23h
    HipoGBM: Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Hospital do Coracao
    New trial
    |
    temozolomide
    23h
    IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (clinicaltrials.gov)
    P2, N=31, Completed, Zhejiang Cancer Hospital
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    Rituxan (rituximab) • dexamethasone • thiotepa
    23h
    RC18_0055: MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma. (2024-515219-23-00)
    P1, N=35, Recruiting, Centre Hospitalier Universitaire De Nantes | Not yet recruiting --> Recruiting
    Enrollment open
    |
    fludarabine IV
    1d
    FLU-CART: Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy (2025-524278-40-00)
    P4, N=75, Not yet recruiting, Universitair Ziekenhuis Gent
    New P4 trial
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Carvykti (ciltacabtagene autoleucel)
    1d
    Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2026 --> Nov 2027
    Trial completion date
    |
    temozolomide
    1d
    SunRISe-4: A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P2, N=163, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2027 --> Mar 2026
    Trial completion date
    |
    cetrelimab (JNJ-63723283) • Inlexzo (gemcitabine intravesical system)
    1d
    Repression of FOSL1 augments ferroptosis to overcome oxaliplatin resistance in colorectal cancer by acting on SRSF2. (PubMed, Mol Biol Rep)
    FOSL1 promotes oxaliplatin resistance in CRC by suppressing ferroptosis through the upregulation of SRSF2. Targeting FOSL1 may represent a novel therapeutic strategy to overcome oxaliplatin resistance in colorectal cancer.
    Journal
    |
    SRSF2 (Serine and arginine rich splicing factor 2) • GPX4 (Glutathione Peroxidase 4) • FOSL1 (FOS Like 1) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    oxaliplatin
    1d
    Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation. (PubMed, Mol Oncol)
    We found a p53-mediated downregulation of the Solute Carrier Family 7 Member 11 (SLC7A11)/Cystine/Glutamate Transporter (xCT) expression and glutathione levels. Our results suggest that combined administration of DMF and cisplatin, by targeting the dependency of cervical cancer cells on glutathione and (re)activating p53, represents a promising anticancer therapeutic strategy.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    cisplatin
    1d
    Remarkable response to radiation in a non-enhancing diffuse pediatric-type high-grade glioma with germline ATM mutation: The role of PET imaging and integrated histological and molecular analysis. (PubMed, Neurooncol Adv)
    The patient received craniospinal radiation with a boost and concurrent temozolomide. She achieved rapid and significant neurologic recovery of function with KPS increasing to 90, accompanied by radiographic improvement. This case highlights the utility of PET/MRI in biopsy planning and underscores the importance of integrated histological and molecular diagnosis for management of non-enhancing gliomas.
    Journal
    |
    ATM (ATM serine/threonine kinase)
    |
    ATM mutation • IDH wild-type
    |
    temozolomide